- Home
- AXSM vs CNS Comparison
AXSM vs CNS Comparison
Compare AXSM & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- CNS
- Stock Information
- Founded
- AXSM 2012
- CNS 1986
- Country
- AXSM United States
- CNS United States
- Employees
- AXSM N/A
- CNS N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- CNS Investment Managers
- Sector
- AXSM Health Care
- CNS Finance
- Exchange
- AXSM Nasdaq
- CNS Nasdaq
- Market Cap
- AXSM 4.2B
- CNS 4.7B
- IPO Year
- AXSM 2015
- CNS 2004
- Fundamental
- Price
- AXSM $84.60
- CNS $86.41
- Analyst Decision
- AXSM Strong Buy
- CNS Hold
- Analyst Count
- AXSM 14
- CNS 3
- Target Price
- AXSM $125.54
- CNS $92.00
- AVG Volume (30 Days)
- AXSM 893.5K
- CNS 191.2K
- Earning Date
- AXSM 02-18-2025
- CNS 01-22-2025
- Dividend Yield
- AXSM N/A
- CNS 2.76%
- EPS Growth
- AXSM N/A
- CNS 0.80
- EPS
- AXSM N/A
- CNS 2.68
- Revenue
- AXSM $338,457,000.00
- CNS $496,822,000.00
- Revenue This Year
- AXSM $44.77
- CNS $7.00
- Revenue Next Year
- AXSM $67.70
- CNS $17.56
- P/E Ratio
- AXSM N/A
- CNS $32.20
- Revenue Growth
- AXSM 51.47
- CNS 0.21
- 52 Week Low
- AXSM $64.11
- CNS $64.13
- 52 Week High
- AXSM $105.00
- CNS $110.67
- Technical
- Relative Strength Index (RSI)
- AXSM 43.66
- CNS 30.38
- Support Level
- AXSM $79.19
- CNS $82.85
- Resistance Level
- AXSM $87.53
- CNS $93.19
- Average True Range (ATR)
- AXSM 4.37
- CNS 1.96
- MACD
- AXSM -0.02
- CNS -0.57
- Stochastic Oscillator
- AXSM 61.27
- CNS 29.57
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.